Mayne Pharma Group (ASX:MYX) rejected Cosette Pharmaceuticals' Tuesday notice to terminate the scheme implementation deed (SID) for the proposed acquisition of the company, according to a Wednesday filing with the Australian bourse.
It rejected the notice as invalid as Cosette is not entitled to terminate the SID, the filing said.
The company attempted to engage in consultation with Cosette, but has not been able to reach an agreement for the scheme to proceed, the filing added.